Focus: Verona Pharma is a UK-based public pharmaceutical company specializing in small-molecule therapies for respiratory indications. The company has one marketed product (Ensifentrine/OHTUVAYRE) and maintains an active clinical pipeline across multiple therapeutic areas.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Hot — 1737 jobs added in 30d
Net +425 (1737 new, 1312 removed). Aggressive expansion phase.
A viable mid-cap pharma employer with growth hiring and respiratory expertise, but data quality issues and narrow product portfolio warrant diligence before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Lead marketed product; small-molecule PDE3i with 20-year exclusivity runway; represents primary near-term revenue pillar.
Help build intelligence for Verona Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Verona Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms - BioSpace
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms BioSpace
8-K Filing: Merck & Co., Inc. (MRK) (CIK 0000310158) — EXHIBIT 99.1
EXHIBIT 99.1
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials).
Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo